Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Summit Therapeutics Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.29 (market cap $510.01M), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 26.9× GraniteShares 2x Long COIN Daily ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Summit Therapeutics Inc for 16 Days on average.
| CONL | SMMT | |
|---|---|---|
Market Cap | $510.01M | $13.71B |
Volume | 21,041,836 | 6,173,057 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $26.38 |
52-Week Low | $3.93 | $12.43 |
Typical Hold Time | 15 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL, a leveraged ETF tracking COIN, trades at $5.26, up 0.57% today. Technical indicators show mixed signals with a bearish overall trend but bullish oscillators including oversold RSI readings. The stock faces resistance at $5 and support at $4. Recent news highlights volatility with significant price gaps and volume spikes.
Outlook remains highly volatile given the leveraged structure and dependence on COIN performance. Investment opportunities exist for short-term traders capitalizing on momentum swings, but risks include amplified losses, regulatory uncertainty, and crypto market sensitivity. Long-term investors should approach with caution.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
